Acadia Pharmaceuticals | ACAD - Interest Expense On Debt


Acadia Pharmaceuticals reported $0 in Interest Expense on Debt for its fiscal quarter ending in September of 2024.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
ALKERMES USD 4.65M 1.35M Dec/2024
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.78M 199K Dec/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Cara Therapeutics 43.75M 4.8M Jun/2025
Corcept Therapeutics USD 823.61M 21.88M Sep/2025
Cytokinetics USD 26.32M 2.06M Sep/2025
Eisai JPY 1.43B 12M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Incyte USD 582K 10K Dec/2025
J&J USD 18M 290M Sep/2025
Moderna USD 12.14B 12.13B Sep/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Pfizer USD 711M 59M Dec/2025
Prothena USD 352.63M 46.44M Sep/2025
PTC Therapeutics USD 50.58M 2.59B Dec/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Ultragenyx Pharmaceutical USD 19M 4.85M Dec/2025
Vanda Pharmaceuticals 601.14M 23.61M Sep/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025